NCT07201467View on ClinicalTrials.gov

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

August 15, 2027

Study Completion Date

December 15, 2027

Conditions

End-Stage Renal Disease Requiring Haemodialysis

Interventions

DRUG

KN060

pharmacokinetic and pharmacodynamic characteristics of KN060 in ESRD on Hemodialysis

Trial Locations (1)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Suzhou Alphamab Co., Ltd.

INDUSTRY

NCT07201467 - To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients | Biotech Hunter | Biotech Hunter